Due to the unique side-effect profile of immune checkpoint inhibitors (ICIs). groups of patients deemed to be at high risk of complications were excluded from trials that proved the efficacy and safety of these agents in patients with various malignancies. Among these excluded patients were those with prior solid organ transplantation. chronic viral infections and pre-existing autoimm... https://www.nacrack.com/